生物兵器防御用ワクチンの世界市場:炭疽菌ワクチン、天然痘ウイルスワクチン、その他

◆英語タイトル:MarketVIEW: Biodefense vaccines - Global vaccine overview
◆商品コード:VACZ51101
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2015年9月
◆ページ数:90
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,865 ⇒換算¥572,020見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Since the 2001 terrorist attacks and continued threats at a global level against many Western governments, the concept of biodefense has become an important component of many national countermeasure strategies. To this end, a number of chemical, biologica1 , radiological, and nuclear (CBRN) terrorism agents were identified as part of a new US law passed in 2004 known as the Project Bioshield Act. This act allowed the US government to guarantee a market for CBRN countermeasures, which up until June 2014 obligated approximately $3.309 bn in funding.

Despite Project Bioshield and The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), which has effectively extended the Project BioShield procurement program to FY2018, the US HHS has obligated 90% to just three threats: anthrax, smallpox, and botulinum toxin. Project BioShield did not acquire any countermeasures against the other eight material CBRN threats, meaning that a significant amount of research and development is still required.

This MarketVIEW report covers in depth the background, legislation and current US capabilities with regard to biodefense vaccines with a focus on anthrax, smallpox and other biodefense vaccines. For anthrax and smallpox, detailed coverage is provided on disease epidemiology, past and current vaccines/associated recommendations/policy and corporate development of new generation vaccines for inclusion to the future US Strategic National Stockpile. The objective of this report is to give the reader a full background into the biodefense industry so that future dynamics/trends can be visualized for potential strategy development or market entry.

【レポートの目次】

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV063_TOC_150824.pdf

****This product is composed of two forecast models and a summary presentation

Author’s note
Contents
Executive summary
Summary table of biodefence vaccines
Authors note
What is biodefense?
Key events in US biodefense policy
The US Project Bioshield Act
CBRN Agents Determined to Pose a Material Threat
Use of FY2004-FY2013 advance appropriations ($m)
Project BioShield Acquisition Activity
Project BioShield Countermeasure Acquisition by Threat FY2004-FY2014 ($m)
The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA)
Other important US Biodefense legislation
Biomedical Advanced Research and Development Authority (BARDA)
BARDA – progress since 2004
Attributes of biodefense vaccines
Technology support to biodefense vaccines (US BARDA)
Next generation concepts (US BARDA)
Biodefense vaccines: US Capabilities
US HHS Centers for Innovation in Advanced Development and Manufacturing (CIADMs)
CIADM: Texas A&M University System (TAMUS)
CIADM: ex-Novartis Vaccines and Diagnostics, Cambridge MA
CIADM: Emergent Biosolutions, Gathersburg, MD
CIADMs – summary map
US Department of Defense (DoD) – CBD program
Biodefense vaccines: anthrax
Anthrax: disease background
Types of anthrax
Anthrax: US incidence
Anthrax and bioterrorism
Anthrax: management (general)
History of anthrax vaccines: US
History of anthrax vaccines: detailed timeline
Anthrax vaccine: recommended groups (ACIP – 2009)
Focus on AVA vaccine: Biothrax pre-exposure schedule
Anthrax: Post-exposure prophylaxis (PEP)
Anthrax vaccines: current and future research
HHS PHEMCE anthrax programmatic priorities
Next generation Anthrax vaccines: NuThraxTM
Next generation Anthrax vaccines: PreviThraxTM
Next generation Anthrax vaccines: Soligenix
Ad5 Vectored Anthrax vaccine – NasoShield (VAXIN)
Pfenex Inc (Px563L)
PharmAthene: SparVax rPA Anthrax Vaccine
Market for Anthrax vaccines
Anthrax supply contracts: Emergent Biosolutions
Emergent Biosolutions: product sales 2012 – 2014, Biothrax
Emergent Biosolutions – spinout
Biodefense vaccines: smallpox
Smallpox: disease background
Types of smallpox
Smallpox disease symptoms
Vaccination and smallpox
Conventional smallpox vaccines
WHO smallpox eradication campaign
Smallpox: six preconditions for eradication met
Smallpox vaccines and biodefense
Smallpox as a weapon: former USSR
Global smallpox vaccine stockpiles (2005)
Second generation smallpox vaccines
Third generation smallpox vaccines
Bavarian Nordic: MVA-BN
MVA-BN and US Project Bioshield
Bavarian Nordic: US contracts awarded to date
MVA-BN and Canada/EU/ROW
IMVANEX: revenue potential at high threat level
IMVAMUNE: life cycle management
Other key vaccines: Kaketsuken Japan: LC16m81
History of Smallpox Vaccine Preparedness in Japan
Kaketsuken Japan: LC16m8 – US BARDA program
Other biodefense vaccines
Botulinum toxin vaccine
Tularemia vaccines
Ricin vaccines
Burkholderia vaccines
Alphaviruses and biodefense vaccines
Bibliography
About VacZine Analytics
Disclaimer

*** PAGES: ~90 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form



【レポートのキーワード】

生物兵器防御用ワクチン、炭疽菌、天然痘ウイルス、炭疽菌ワクチン、天然痘ウイルスワクチン、生物兵器、生物テロ防御、細菌、ウイルス、ボツリヌス毒素ワクチン、野兎病ワクチン、リシンワクチン、バークホルデリアワクチン、防衛

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 生物兵器防御用ワクチンの世界市場:炭疽菌ワクチン、天然痘ウイルスワクチン、その他(MarketVIEW: Biodefense vaccines - Global vaccine overview)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆